Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018125950) A COMBINATION THERAPY FOR TREATING CANCER
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

claimed is:

A method of treating a subject having non-small cell lung cancer, the method comprising administering to the subject a therapeutically effective amount of a composition, wherein the composition comprises demethylated

polymethoxyflavone or polymethoxyflavone and taxane.

The method of claim 1, wherein the demethylated polymethoxyflavone is 5-demethylpolymethoxyflavone.

The method of claim 1, wherein the demethylated polymethoxyflavone is 5-demethylhesperetin, 5-demethylnobiletin, 5-demethylsinensetin, 5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone, 5-hydroxy-3,6,7,3',4'-pentamethoxyflavone, 5-hydroxy-6,7,4'-triamethoxyflavone, 7-demethylpolymethoxyflavone, 6-demethylpolymethoxyflavone, 8-demethylpolymethoxyflavone, 3'-demethylpolymethoxyflavone, 4'-demethylpolymethoxyflavone, 3-demethylpolymethoxyflavone, 3',4'-bis-demethylpolymethoxyflavone, 5,4'-bis-demethylpolymethoxyflavone, or a combination thereof.

The method of claim 1, wherein the polymethoxyflavone is hesperetin, nobiletin, 3,5,6,7,8,3',4'-heptamethoxyflavone, sinensetin, 3,5,6,7,3',4'-hexamethoxyflavone, 5,6,7,4'-tetramethoxyflavone, 3,5,6,3',4'-pentamethoxyflavone, or a combination thereof.

The method of claim 1, wherein the taxane is paclitaxel, docetaxel, or a combination thereof.

The method of claim 1, wherein the composition comprises 5-demethylnobiletin and docetaxel.

7. The method of claim 6, wherein the 5-demethylnobiletin is administered in an amount of 6.3 μιηοΙ/L -15.5 μιηοΙ/L and the docetaxel is administered in an amount of 3.125 nmol/L -25 μιηοΙ/L.

8. The method of claim 7, wherein the 5-demethylnobiletin is administered in an amount of 10 μιηοΙ/L and the docetaxel is administered in an amount of

6.7 μιηοΙ/L.

9. A method of inhibiting lung cancer cells, the method comprising contacting the lung cancer cells with a therapeutically effective amount of a composition, wherein the composition comprises demethylated polymethoxyflavone or polymethoxyflavone and taxane.

10. The method of claim 9, wherein the composition comprises 5-demethylnobiletin and docetaxel.

11. The method of claim 10, wherein the lung cancer cells comprises human lung cancer cell CLl-5.

12. The method of claim 10, wherein the lung cancer cells comprises transplanted human lung cancer cell CLl-5 in a laboratory animal, wherein the laboratory animal is a BALB/c nude mouse.